Business Context and Reporting Period
This Form 8-K filing by Inmune Bio, Inc. (INMB) is dated May 30, 2019. The report addresses a regulatory matter concerning the company's compliance with Nasdaq Listing Rule 5635(c) regarding the issuance of shares to officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific securities transaction and regulatory compliance status.
Material Changes and Events
- Initial Transaction: On May 6, 2019, the Company entered into Securities Purchase Agreements with CEO Raymond J. Tesi (11,100 shares) and CFO David Moss (5,000 shares) at a price of $9.00 per share.
- Regulatory Deficiency: Nasdaq issued a Deficiency Letter stating the Company failed to comply with Listing Rule 5635(c), which requires shareholder approval for issuing shares to officers at a discount to the prior day's closing bid price.
- Remedial Action: The Company amended the purchase agreements on May 17, 2019, and May 24, 2019. The purchase price for Mr. Moss was increased to $10.71 per share, and for Mr. Tesi to $10.75 per share. These prices reflect the closing bid price on the date prior to issuance, thereby eliminating the need for shareholder approval.
- Resolution: On May 30, 2019, the Nasdaq Listing Qualifications Staff notified the Company that it has regained compliance with Listing Rule 5635(c).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The primary contingency addressed was the potential delisting or failure to satisfy continued listing standards, which has been resolved.
Investor Verification Checklist
- Verify the final share count and total capital raised from the amended transactions with CEO Tesi and CFO Moss.
- Confirm the current trading status of INMB on the NASDAQ Stock Market LLC to ensure no further listing restrictions exist.
- Review the amended Securities Purchase Agreements to confirm the exact closing bid prices used for the price adjustments ($10.71 and $10.75).